2025-12-04 - Analysis Report
Okay, let's break down this analysis of Natera (NTRA).

**0) Simple Numbers & Analysis**

**1) Return Rate Comparison**

*   **Ticker:** NTRA (Natera Inc)
*   **Company Overview:** Natera is a genetic testing company focused on non-invasive prenatal testing (NIPT) and cancer screening.
*   **NTRA Cumulative Return:** 142.74%
*   **VOO (S&P 500) Cumulative Return:** 100.84%
*   **Divergence:**
    *   Current: 43.6
    *   Relative Divergence: 50.2

**Analysis:** NTRA has significantly outperformed the S&P 500 (VOO) over the period examined. The current divergence of 43.6 percentage points indicates a substantial difference in returns. The relative divergence of 50.2 suggests that the current divergence is in the middle range of its historical fluctuations.

**Alpha, Beta Analysis**

|            | CAGR      | MDD     | Alpha     | Beta   | Cap(B) |
| :--------- | :-------- | :------ | :-------- | :----- | :----- |
| 2015-2017  | -10.0%    | 70.1%   | -34.0%    | -0.2   | 1.2    |
| 2016-2018  | 22.0%     | 80.0%   | 6.0%      | 0.1    | 1.9    |
| 2017-2019  | 50.0%     | 80.0%   | 28.0%     | 1.0    | 4.7    |
| 2018-2020  | 186.0%    | 80.5%   | 163.0%    | 1.1    | 13.7   |
| 2019-2021  | 96.0%     | 80.5%   | 49.0%     | 1.6    | 12.9   |
| 2020-2022  | -77.0%    | 80.5%   | -76.0%    | 0.1    | 5.5    |
| 2021-2023  | -194.0%   | 76.6%   | -195.0%   | -1.1   | 8.7    |
| 2022-2024  | 8.0%      | 76.6%   | -13.0%    | -1.2   | 21.9   |
| 2023-2025  | 170.0%    | 76.6%   | 105.0%    | 0.1    | 32.7   |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** Highly volatile, ranging from -194% to +186%. Recent periods (2021-2023) show significant underperformance, but the most recent (2023-2025) shows a strong rebound.
*   **MDD (Maximum Drawdown):** Consistently high drawdowns (around 80%) suggest significant price volatility and risk.
*   **Alpha:** Varies considerably, indicating periods of both outperformance (positive alpha) and underperformance (negative alpha) relative to the market.
*   **Beta:** The Beta values fluctuate, showing that NTRA's correlation to the market varies over time. A beta above 1 indicates that NTRA is more volatile than the market.
*   **Cap(B):** Market capitalization is growing, particularly in more recent years.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 236.91
*   **Last Market Data:** price: 236.87, previousClose: 236.64, change: 0.1
*   **5-day SMA:** 237.312
*   **20-day SMA:** 217.177
*   **60-day SMA:** 190.3712

**Analysis:** The stock price is trading slightly below its 5-day SMA, but significantly above its 20-day and 60-day SMAs. This suggests a short-term consolidation after a recent uptrend. The price has consistently risen over the last 60 days

**3) RSI, PPO, and Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 77.04 (Overbought)
*   **PPO:** 0.4671
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (4 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** 1.7 (+) - short-term increase
*   **Expected Return (%):** -46.4% (negative excess return expected over S&P 500, long-term).

**Analysis:**

*   The Market Risk Indicator suggests a favorable environment for investment.
*   The RSI indicates that the stock is overbought, which could signal a potential pullback.
*   The recent relative divergence change indicates a short-term upward trend.
*   Despite the positive MRI, the Expected Return is negative, suggesting that, according to the model, NTRA is expected to underperform the S&P 500 in the long run. This could be due to a variety of factors, including valuation concerns or expectations of slowing growth.

**4) Recent News & Significant Events**

*   **ASH 2025 Presentation:** Positive data presentation on Lymphoma.
*   **Stock Down:** Article explaining a recent stock drop.
*   **Hold Rating:** Article discussing a "Hold" rating despite growth.
*   **Morgan Stanley Price Target Increase:** Bullish signal from Morgan Stanley.
*   **Analyst Price Target:** New analyst forecast with a target price.
*   **Insider Selling:** Article discussing potential insider selling activity.

**Analysis:** The news is a mixed bag. Positive catalysts include the ASH presentation, and Morgan Stanley's price target increase. However, the presence of articles discussing a stock drop, a "Hold" rating, and potential insider selling are cause for concern.

**4-2) Analyst Opinions**

*   **Consensus:** Strong Buy (1.47)
*   **Opinions:** 19
*   **Target Price (avg/high/low):** 237.05 / 280.00 / 186.00

**Analysis:**  The analyst consensus is strongly bullish, with an average target price very close to the current price.  This suggests that analysts, on average, believe the stock is fairly valued at its current level.

**5) Recent Earnings Analysis**

| Date       | EPS   | Revenue    |
| :--------- | :---- | :--------- |
| 2025-11-07 | -0.64 | 0.59 B$    |
| 2025-08-08 | -0.74 | 0.55 B$    |
| 2025-05-09 | -0.5  | 0.50 B$    |
| 2024-11-12 | -0.26 | 0.44 B$    |
| 2025-11-07 | -0.26 | 0.44 B$    |

**Analysis:** While revenue has generally been increasing, Natera is still reporting losses per share (EPS).

**6) Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
| :--------- | :-------- | :------------ |
| 2025-09-30 | $0.59B    | 64.91%        |
| 2025-06-30 | $0.55B    | 63.41%        |
| 2025-03-31 | $0.50B    | 63.12%        |
| 2024-12-31 | $0.48B    | 62.94%        |
| 2024-09-30 | $0.44B    | 61.79%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE       |
| :--------- | :-------- | :-------- |
| 2025-09-30 | $1.25B    | -6.99%    |
| 2025-06-30 | $1.25B    | -8.10%    |
| 2025-03-31 | $1.24B    | -5.40%    |
| 2024-12-31 | $1.20B    | -4.50%    |
| 2024-09-30 | $0.88B    | -3.60%    |

**Analysis:**

*   **Revenue:** Showing consistent growth.
*   **Profit Margin:**  Very high and improving, indicating strong pricing power.
*   **Equity:** Steadily increasing.
*   **ROE (Return on Equity):** Negative, which is consistent with the negative EPS figures.

**7) Comprehensive Analysis (Summary)**

Natera (NTRA) presents a mixed picture:

*   **Positives:**
    *   Significant outperformance of the S&P 500 historically.
    *   Strong revenue growth and high/improving profit margins.
    *   Bullish analyst consensus.
    *   Positive data presentation and price target increases.
    *   High MRI.
*   **Negatives:**
    *   High historical volatility (MDD).
    *   Negative EPS and ROE.
    *   Overbought RSI.
    *   Negative expected return in the long term.
    *   Recent stock drop and "Hold" ratings indicate potential concerns.
    *   Potential insider selling.

**Overall:**

NTRA is a high-growth, high-risk stock. The company is making progress in revenue and profitability, but is not yet profitable. The analyst consensus is bullish, but the negative expected return suggests that the stock may be overvalued. Investors should carefully consider their risk tolerance and investment horizon before investing in NTRA. The high volatility and mixed signals suggest that this stock is best suited for investors with a high-risk tolerance and a long-term investment horizon. A close watch on future earnings reports will be crucial to determining whether the company can achieve profitability.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.